Literaturhinweise

hämotherapie Ausgabe 11 2008

Bedeutung der neuen Variante der Creutzfeldt-Jakobschen-Erkrankung in der Transfusionsmedizin

1) *Wells GA, Scott AC, Johnsonn CT, Gunning RF, Hancock RD, Jeffrey M, Dawson M, Bradley R. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987;121:419-420*

2) *Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: studies on the epidemiological orign. Vet Rec 1991;128:199-203*

3) *Auer F, Blümel J, Burger R, Buschmann A, Dietz K, Heiden M, Hitzler WE, Klamm H, Kreil Th, Kretzschmar H, Nübling M, Offergeld R, Pauli G, Schottstedt V, Seitz R, Volkers P, Zerr I. Overall Blood Supply Strategy with Regard to Variant Creutzfeld-Jacob Disease (vCJD). Transfus Med Hemoth 2006;33 (suppl 2); 1-39*

4) *Roucou X, LeBlanc AC. Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med 2005;83:3-11*

5) *McBride PA, Schulz-Schaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, Beekes M. Early spread of scrapie form the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J. Virol 2001;75;9320-9327*

6) *Zou S, Fang CT, Schonberger LB. Transfusion Transmission of Human Prion Diseases. Transf Med Rev 2008;22:58-69*

7) *The National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU): Variant Creutzfeldt-Jakob Disease. Current data. www.cjd.ed.ac.uk/vcjdworld.htm.*

8) *Hilton DA, Ghani A, Conyers L, Edwards P, McCardle LM, Ritchie D, Penney M, Hegazy D, Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Path 2004;203:733-739*

9) *Ironside JW, Bishop MT, Conolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM, Hilton DA. Variant Creutzfeldt-Jakob disease: Prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006;332:1186-1188*

10) *Hamaguchi T, Noguchi-Shinohara M, Nozaki I, Nakamura Y, Sato T, Kitamoto T, Mizusawa H, Yamada M. Medical procedures and risk for sporadic Creutzfeldt-Jakob disease Japan 1999-2008. Emerg Infect Dis 2009;15:265-271*

11) *Dorsey K, Zou S, Schonberger LB, Sullivan M, Kessler D, Notari IV E, Fang CT, Dodd RY. Lack of evidence of transfusion transmission of Creutzfeld-Jakob disease in a US surveillance study. Transfusion 2009;49:977-984*

12) *Hunter N, Forster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. J Gen Virol 2002;83:2897-2905*

13) *Bons N, Lehmann S, Mestre-Frances N, Dormont D, Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to primate Microcebus murinus. Transfusion 2002;42:513-516*

14) *Herzog C, Sales N, Etchegaray N, Charbonnier A, Freire S, Dormont D, Deslys JP, Lasmezas CI. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 2004;363:422-428*

15) *Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004;10 (suppl 4):64-69*

16) *Siso S, Gonzales L, Houston F, Hunter N, Martin S, Jeffrey M. The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion. Blood 2006;108:745-748*

17) *Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000;356:999-1000*

18) *Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, Siso S, Gonzalez L, Jeffrey M, Hunter N. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008;112:4379-4745*

19) *Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 2006;91:348*

20) *Paul-Ehrlich-Institut. Informationen zu Gerinnungsfaktoren und Prionen. www.pei.de/cln_115/nn_154580/DE/infos/fachkreise/am-infos-ablage/sik/2005-01-02-haemate-info.html?_nnn=true*

21) *Ironside JW. Creutzfeldt-Jakob Disease. Treatment Hemophilia 2009;49:1-14*

22) *Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001;294:1726-1728*

23) *Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, Hilton DA, Ironside JW, Edwards P, McCardle LM, Ritchie DL, Dabaghian R, Ambrose HE, Gill ON. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 2009;338:b1142*

24) *Alperovitch A, Will RG. Predictiong the size of vCJD epidemic in France. CR Biol 2002;325:33-36*

25) *Chadeau-Hyam M, Tard A, Bird S, Le Guennec S, Bemrah N, Volatier JL, Alperovitch A. Estimation of the exposure of the French population to BSE agent: comparison of the 1980-95 consumption of beef products containing mechanically recovered meat in France and the UK, by birth cohort and gender. Stat Methods Med Res 2003;12:247-260*

26) *Chadeau-Hyam M, Alperovitch A. Risk of variant Creutzfeldt-Jakob disease in France. Int. J Epidemiol 2005;34:46-52*

27) *Lefrère JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009;49:797-812*

28) *Seitz R, Auer F, Blümel J, Burger R, Buschmann A, Dietz K, Heiden M, Hitzler WE, Klamm H, Kreil Th, Kretzschmar H, Nübling M, Offergeld R, Pauli G, Schottstedt V, Volkers P, Zerr I. Impact of vCJD on blood supply. Biologicals 2007;35:79-97*

29) *Dietz, K, Raddatz G, Wallis J, Mueller N, Zerr I, Duerr HP, Lefèvre H, Siefried E, Loewer J. Blood transfusion and spread of variant Creutzfeldt-Jakob disease. Emerg Inf Dis 2007;13:89-96*

30) *Clarke C, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? J R Soc Interface 2007;4:675-684*

31) *Garske T, Ward HJT, Clarke P, Will RG, Ghani AC. Factors determining the potential for onward transmission of variant Creutzfeldt-Jakob disease via surgical instruments. J R Soc Interface 2006;3:757-766*

32) *Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Deutscher Ärzte-Verlag 2007*

33) *Coste J, Prowse C, Eglin R, Fang C. A report on transmissible spongiform encephalopathies and transfusion safety. Vox Sang 2009;96:284-291*

34) *Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfusion Clin Biol 2006;13:320-328*

35) *Brown P, Rohwer RG, Dunstan BX, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998;38:810-816*

36) *Stenland CJ, Lee DC, Petteway SR, Rubinstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002;42:1497-1500*

37) *Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004;32:1-10*

38) *Stellungnahme zum Risiko der Übertragung von vCJK durch Plasmaderivate aus humanem Plasma (Mitteilungen des Arbeitskreises Blut des Bundesministeriums für Gesundheit). Bgbl 2009;52:648-649*

39) *Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004;364:529-531*

40) *Prowse C. Prion removal with filter. ISBT Science Series 2006;1:230-234.*

41) *Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, Meeker C, Carp R. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang 2006;90:265-275*

42) *Beekes M, Blümel J, Burger R, v Dewitz C, Gröner A, Heiden M, Kretzschmar H, Nübling M, Schlenkrich U, Schottstedt V, Seitz R, Strobel J, Willkommen H, Wirsing von König CH, Zerr I. Report of the working group „Overall blood supply strategy with regard to variant Creutzfeldt-Jakob Disease (vCJD)". Transfus Med Hemother 2009;36:79-93*

43) *Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med 2005;11:982-985*

44) *Saa P, Castilla J, Soto C. Presymptomatic detection of Prions in Blood. Science 2006;313:92-94*

45) *Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA,Caughey B. Ultrasensitive detection of scrapie protein using seed conversion of recombinant prion protein. Nat Meth 2007;4:645-650*

46) *Pan T, Li R, Wong BS, Kang SC, Ironside J, Sy MS. Novel antibody enzyme-linked immunosorbent assay that distinguishes prion protein in sporadic and variant cases of Creutzfeldt-Jakob disease. J Clin Microbiol 2005;43:1118-1126*

47) *Gregori L, Gray BN, Rose E, Spinner DS, Kascsak RJ, Rohwer RG. A sensitive and quantitative assay for normal PrP in plasma. J Virol Meth 2008;149:251-259*

48) *Fagge T, Barclay GR, MacGregor I, Head M, Ironside J, Turner M. Variation in concentration of prion protein in the peripheral blood of patients with variant and sporadic Creutzfeldt-Jakob disease detected by dissociation enhanced lanthanide fluoroimmunoassay and flow cytometry. Transfusion 2005;45:504-513*

49) *Varshney M, Waggoner PS, Tan CP, Aubin K, Montagna RA, Craighead HG. Prion protein detection using nanomechanical resonator arrays and secondary mass labelling. Anal Chem 2008;80:2141-2148*

50) *Minor P, Newham J, Jones N, Bergeron C, Gregori L, Asher D, van Engelenburg F, Stroebel T, Vey M, Barnard G, Head M. Standards for the assay of Creutzfeldt-Jakob disease specimens. J Gen Virol 2004;85:1777-1784*

51) *Cooper JK, Ladhani K, Minor PD. Reference materials for the evaluation of pre-mortem variant Creutzfeldt-Jakob disease diagnostic assays. Vox Sang 2007;92:302-310*

52) *Akimov S, Yakovleva O, Vasilyeva I, McKenzie C, Cervenakova L. Persistent propagation of variant Creutzfeldt-Jakob disease agent in murin spleen stromal cell culture with features of mesenchymal stem cells. J Virol 2008;82:10959-10962*

53) *v Dewitz C. Legal and ethical aspects regarding the development and application of screening assays to detect vCJD infections. www.karger.com/doi/10.1159/000188082*

54) *Hewitt PE. Implications of notifying donors and recipients. Vox Sang 2004;87(suppl 2):S1-S2*

55) *Health Protection Agency, UK. Consultation on a new vCJD test for blood donors. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733832029?p=1225960597236*